Summer 2018
Vol 116.1

Responding to the Opioid Addiction

Crisis in New Jersey

Seabrook® Expands Detox Program

Joseph N. Ranieri, DO, FASAM, FAAFP, Diplomat - ABAM is Seabrook Medical Director, and leads the medical and clinical teams at Seabrook.

 

He is assisted by Director of Medical Services, William Bruck, MSN, APN, FNP-BC, PMP, along with a team of psychiatric nurse practitioners, physician assistants and more than 20 registered nurses.

For more information please visit www.Seabrook.org, or call the 24-hour help line at 1-800-761-7575.

Seabrook addiction treatment center has applied to the State of

New Jersey, DHS, Office of Licensing, to add an additional 13 licensed

residential detox beds to its already existing 37 licensed beds at their

Bridgeton, NJ location. This expansion will address head on the demand

for treatment services for those addicted to opioids and other substances.

 

The new capacity of 50 licensed beds will be housed in two separate

buildings on the Bridgetonmain campus. The Seabrook medical building

will maintain its current capacity of 29 beds. Theadditional 21 beds will be

located in the 42,000 sq. ft. Recovery Center building. The program will offer

gender separate accommodations, in both private and semi-private rooms,

addressingwithdrawal management from all substances including alcohol,

benzodiazepines, like Xanax and valium and barbiturates. Seabrook will expand

its capacity to manage the withdrawal of patients dependent on opioids such as

heroin and prescription pain relievers, morphine, codeine and semi-synthetic

opioids like oxycodone and hydrocodone. Lengths of stay will range from four

days to 15 days, depending on the severity of the withdrawal symptoms.

 

Following completion of the detox program, patients may enter into the Seabrook residential rehab program or outpatient programs, return home or transition to a sober living home and enroll in a local outpatient program. Patients are not required to enroll in Seabrook aftercare programs. Seabrook detox programs are designed to meet the definition of the American Society of Addiction Medicine Level 3.7.

 

Defined as medically monitored intensive inpatient services, providing 24-hour nursing care, physician and other medical and clinical practitioners, available to address the biomedical, emotional, behavioral and cognitive problems. Patients at this level of care require medication because their symptoms are so severe. Laboratory testing is used to assess recent substance use. This will include urine alcohol and drug screen, testing for liver enzymes, serum bilirubin, serum creatinine, as well as tests for hepatitis B and C and HIV.2






 

 

 

Level 3 also encompasses residential services described as co-occurring capable, which are staffed by designated addiction treatment, mental health and general medical personnel who provide a range of services.

 

A proven and effective response to both opioid use disorder as well as alcohol-related disorders is Medication-Assisted Treatment (MAT). A common misconception associated with MAT is that it substitutes one drug for another. Instead these medications relieve withdrawal symptoms and psychological cravings that cause chemical imbalances in the body. It is the use of medications, in combination with behavioral therapies, to provide a whole-patient approach.

 

Individuals receiving MAT often demonstrate dramatic improvement in addiction related behaviors and psychosocial functioning1. Seabrook administers the medication buprenorphine for both short-term stabilization as well as long-term maintenance for those diagnosed with opioid use disorder. In some instances, methadone may be a more effective medication. Acamprosate calcium is a medication used specifically to reduce the physical and emotional distress that can occur in the weeks and months after alcohol consumption has stopped. Naltrexone is a

medication used to treat both opioid and alcohol use disorders. It blocks the euphoric effects and the feelings of intoxication and sedation, as well as reducing cravings. Extended-release injectable naltrexone (Vivitrol®) is a long acting formulation administered as a once-monthly injection.

 

To assist in the increased demand and volume, Seabrook is expanding both the care management and transportation departments. For the convenience of patients and their families, transportation is offered for day, evening and weekend admissions, typically within a 4-hour radius. Care managers begin the discharge planning on the first day of admission. Early discharge planning assures a smooth and successful transfer and discharge process.

© 2018 New Jersey Association of Osteopathic Physicians and Surgeons

The Journal is the official magazine of the New Jersey Association of Osteopathic Physicians and Surgeons (NJAOPS). NJAOPS is the sixth largest state affiliate of the American Osteopathic Association. NJAOPS represents the interests of more than 4,700 active osteopathic physicians, residents, interns and medical students. Founded in 1901, NJAOPS is one of the most active medical associations in New Jersey with 12 county societies.